close

LATEST POSTS from Anne-Lise Berthier

New CEO for Polyplus-transfection

New CEO for Polyplus-transfection Polyplus-transfection, a leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, named Mario Philips as Chief Executive Officer. He succeeds Karsten Wilking, who will transition into a strategic advisor role. Prior to this appointment, Mario Philips served as CEO of…..

EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment   The European Investment Bank (EIB) and Atriva Therapeutics, a german biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement  to facilitate the company’s development and clinical testing of…..

Positive CHMP opinion for gene therapy Libmeldy™ for the treatment of Early-Onset Metachromatic Leukodystrophy

Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending full, or standard, marketing authorization for Libmeldy® (cryopreserved autologous CD34+ cells encoding the arylsulfatase-A, or ARSA,…..

Trend Chart On Innovative Bioindustries September 2020, 17th

Trend Chart On Innovative Bioindustries September 2020, 17th FEATURE STORY ●  Nonclinical studies that support viral vector-delivered gene therapies: An EFPIA Gene Therapy Working Group perspective BASIC SCIENCE ● Paving the road for RNA therapeutics CLINICAL TRIALS/DATAS ● Akcea: Positive phase 2 clinical data of Vupanorsen ● The NEJM publishes…..

G&CTI, premier think tank indépendant sur les thérapies avancées

G&CTI, premier think tank indépendant sur les thérapies avancées Dans l’environnement actuel où les thérapies géniques et cellulaires apparaissent certes comme une véritable révolution médicale, mais où de nombreux défis éthiques, sociétaux, politiques, économiques se posent, la quête de réponses opérationnelles s’impose ! L’ensemble des acteurs (sociétés savantes, patients, industriels,…..

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics Agilent Technologies will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and RNA molecules used to create nucleic acid-based therapeutics. Oligos hold the potential to be used in developing treatments for…..

Evotec – Secarna: new partnership in antisense oligonucleotide-based therapeutics

Evotec-Secarna: new partnership in antisense oligonucleotide-based therapeutics The German companies Evotec and  Secarna Pharmaceuticals have concluded a strategic partnership in the field of antisense oligonucleotide (ASO)-based therapeutics. Secarna, a global leader in discovering and developing next-generation ASO,  combines its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate…..